NCT06479122

Brief Summary

The investigators aim to compare the analgesic efficacy of intravenous acetaminophen alone versus combination of acetaminophen/ibuprofen (Maxigesic®IV) in multimodal analgesia after cesarean section.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for phase_4

Timeline
4mo left

Started Oct 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Oct 2024Aug 2026

First Submitted

Initial submission to the registry

June 18, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 28, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

October 9, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2026

Last Updated

June 4, 2025

Status Verified

June 1, 2025

Enrollment Period

1.7 years

First QC Date

June 18, 2024

Last Update Submit

June 1, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Obstetric QoR-11K score 24 hours after end of surgery

    Minimum 0, poor recovery; maximum 110, good recovery

    24 hours after end of surgery

Secondary Outcomes (15)

  • Numeric rating scale pain score (0-10) 4 hours after end of surgery

    4 hours after end of surgery

  • Numeric rating scale pain score (0-10) 8 hours after end of surgery

    8 hours after end of surgery

  • Numeric rating scale pain score (0-10) 12 hours after end of surgery

    12 hours after end of surgery

  • Numeric rating scale pain score (0-10) 24 h after end of surgery

    24 h after end of surgery

  • Numeric rating scale pain score (0-10) 48 hours after end of surgery

    48 hours after end of surgery

  • +10 more secondary outcomes

Study Arms (2)

Acetaminophen

ACTIVE COMPARATOR
Drug: Acetaminophen

Acetaminophen/Ibuprofen

EXPERIMENTAL
Drug: Acetaminophen/Ibuprofen

Interventions

1g acetaminophen is administered during skin closure (end of operation).

Also known as: Acetaminophen #1
Acetaminophen

A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)

Also known as: Acetaminophen/Ibuprofen #1
Acetaminophen/Ibuprofen

Eligibility Criteria

Age19 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for elective cesarean section
  • Gestational age \> 37+0 weeks

You may not qualify if:

  • Emergency cesarean section
  • Multiple pregnancy (e.g. twins, triplets)
  • Body weight \< 50 kg
  • Preeclampsia
  • History of hypersensitivity to acetaminophen or ibuprofen
  • History of upper gastrointestinal tract bleeding or gastric ulcer
  • Underlying liver disease
  • Underlying kidney disease or GFR \< 90 mL/min/1.73m2
  • Heart failure or severe hypertension
  • History of asthma
  • Chronic use of barbital or tricyclic antidepressants

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Interventions

AcetaminophenIbuprofen

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPhenylpropionatesAcids, CarbocyclicCarboxylic Acids

Central Study Contacts

Junghwa Seo, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 18, 2024

First Posted

June 28, 2024

Study Start

October 9, 2024

Primary Completion (Estimated)

June 25, 2026

Study Completion (Estimated)

August 25, 2026

Last Updated

June 4, 2025

Record last verified: 2025-06

Locations